Regular use of corticosteroids and low use of short-acting β2-agonists can reduce asthma hospitalization

Chest

Volumn 127, Issue 4, 2005, Pages 1242-1251

  Senthilselvan, Ambikaipakan ^a   Lawson, Joshua A ^a,b   Rennie, Donna C ^b   Dosman, James A ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Asthma; Hospitalization; Inhaled corticosteroids; Management; Medications; Short acting 2 agonists

Indexed keywords

AMINOPHYLLINE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; FLUTICASONE; IPRATROPIUM BROMIDE; ISOPRENALINE; KETOTIFEN; NEDOCROMIL; PREDNISOLONE; PREDNISONE; PROCATEROL; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CONTROLLED STUDY; DEMOGRAPHY; DISEASE CONTROL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RISK ASSESSMENT; COHORT ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; ASTHMA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 19044392487     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.4.1242     Document Type: Article

References (36)

1. Boulet LP, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. Canadian Asthma Consensus Group. Can Med Assoc J 1999; 161(suppl):S1-S61
2. Boulet LP, Bai TR, Becker A, et al. What is new since the last (1999) Canadian Asthma Consensus Guidelines? Can Respir J 2001; 8(suppl):5A-27A
3. National Asthma Education Program. Guideline for the diagnosis and management of asthma, expert Panel Report 2. Bethesda, MD: National Heart, Lung, and Blood Institute, 1997; National Institutes of Health publication No. 97-4051
4. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107: 937-944
5. Adams RJ, Fuhlbrigge A, Finkelstein JA, et al. Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma. Pediatrics 2001; 107:706-711
6. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887-891
7. Ishihara K, Hasegawa T, Nishimura T, et al. Increased use of inhaled corticosteroids and reduced hospitalizations in adult asthmatics: 11 years' experience in a Japanese hospital. Respirology 1998; 3:193-197
8. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57:880-884
9. Blais L, Ernst P, Boivin JF, et al. Inhaled corticosteroids and the prevention of readmission to hospital for asthma. Am J Respir Crit Care Med 1998; 158:126-132
10. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268:3462-3464
11. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336
12. Lanes SF, Garcia Rodriguez LA, et al. Respiratory medications and risk of asthma death. Thorax 2002; 57:683-686
13. Blais L, Suissa S, Boivin JF, et al. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma. Thorax 1998; 53:1025-1029
14. Sears MR. Deleterious effects of inhaled β-agonists: short-acting and long-acting agents differ. Chest 2001; 119:1297-1299
15. Eisner MD, Lieu TA, Chi F, et al. β agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001; 17:233-240
16. Shireman TI, Heaton PC, Gay WE, et al. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother 2002; 36:557-564
17. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990; 45:170-175
18. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991; 46:105-111
19. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-506
20. Mullen M, Mullen B, Carey M. The association between β-agonist use and death from asthma: a meta-analytic integration of case-control studies. JAMA 1993; 270:1842-1845
21. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 1994; 149:604-610
22. Suissa S, Blais L, Ernst P. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7:1602-1609
23. Anis AH, Lynd LD, Wang XH, et al. Double trouble: impact of inappropriate use of asthma medication on the use of health care resources. Can Med Assoc J 2001; 164:625-631
24. Ethnocultural and social characteristics of the Canadian population. Ottawa, Ontario: Statistics Canada (data products: dimensions series: 1996 Census of Population), 1999; No. 94F0004XCB96000
25. Demographic information, families. Ottawa. Ontario: Statistics Canada (data products: the nation: 1996 Census of Population), 1998; No. 93F0020XCB96004
26. Downey W, Beck P, McNutt M, et al. Health databases in Saskatchewan. In: Strom BL, ed, Pharmacoepidemiology, 3rd ed. Chichester, UK: Wiley, 2000; 325-345
27. Online formulary. Drug Plan and Extended Benefits Branch, Saskatchewan Health. Available at: http://formulary.drugplan.health.gov.sk.ca/; accessed September 3, 2004
28. Annual statistical report 1999-00. Drug Plan and Extended Benefits Branch, Saskatchewan Health. Available at: http:// formulary.drugplan.health. gov.sk.ca/publications/1999-2000%20Annual%20Report.pdf; accessed September 3, 2004
29. International Consensus Report on diagnosis of treatment of asthma. Bethesda, MD: National Institute of Health, US Dept of Health and Human Services, 1992; National Heart, Blood, and Lung publication 92-3091
30. 2-agonists for the treatment of asthma in Quebec: a population-based utilization review. Chest 2001; 119:1316-1321
31. Dupont WD. Statistical modeling for biomedical researchers: a simple introduction to the analysis of complex data. New York, NY: Cambridge University Press, 2002
32. Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:1016-1018
33. Garrett JE, Lanes SF, Kolbe J, et al. Risk of severe life threatening asthma and β agonist type: an example of confounding by severity. Thorax 1996; 51:1093-1099
34. Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993; 148:75-79
35. 2- agonist use in high-risk inner-city adults with asthma. 2003; 40:367-373
36. Pollack CV Jr, Pollack ES, Baren JM et, al. Multicenter Airway Research Collaboration Investigators. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002; 156:934-940